8:54AM ET 1/14/2022 MT NewswiresPieris Pharmaceuticals (PIRS) said Friday that the first patient has been dosed in the phase two study of its cinrebafusp alfa or PRS-343 product...
7:47AM ET 1/03/2022 MT NewswiresPieris Pharmaceuticals (PIRS) said Monday that part 1a of the sponsor safety review of the company's Phase 2a study of PRS-060/AZD1402, a...
11:04AM ET 11/08/2021 MT NewswiresPieris Pharmaceuticals (PIRS) and Servier said Monday that the first patient has been dosed in the phase 1/2 trial of the tetravalent bispecific fusion...